Oppenheimer Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $221K | Buy |
+6,604
| New | +$164K | ﹤0.01% | 1060 |
|
|
2025
Q4 | – | Sell |
-8,142
| Closed | -$245K | – | 1177 |
|
|
2025
Q3 | $245K | Buy |
8,142
+1,628
| +25% | +$48.8K | ﹤0.01% | 1047 |
|
|
2025
Q2 | $237K | Sell |
6,514
-626
| -9% | -$22.6K | ﹤0.01% | 1043 |
|
|
2025
Q1 | $259K | Buy |
7,140
+1,173
| +20% | +$48.8K | ﹤0.01% | 1002 |
|
|
2024
Q4 | $251K | Sell |
5,967
-524
| -8% | -$26K | ﹤0.01% | 1027 |
|
|
2024
Q3 | $361K | Buy |
6,491
+60
| +0.9% | +$3.06K | ﹤0.01% | 947 |
|
|
2024
Q2 | $264K | Buy |
6,431
+112
| +2% | +$4.78K | ﹤0.01% | 1012 |
|
|
2024
Q1 | $295K | Buy |
6,319
+20
| +0.3% | +$943 | ﹤0.01% | 961 |
|
|
2023
Q4 | $301K | Sell |
6,299
-823
| -12% | -$31.9K | ﹤0.01% | 989 |
|
|
2023
Q3 | $254K | Buy |
7,122
+31
| +0.4% | +$1.23K | ﹤0.01% | 997 |
|
|
2023
Q2 | $327K | Buy |
7,091
+1,850
| +35% | +$85.8K | ﹤0.01% | 951 |
|
|
2023
Q1 | $210K | Buy |
5,241
+108
| +2% | +$4.63K | ﹤0.01% | 1047 |
|
|
2022
Q4 | $238K | Buy |
+5,133
| New | +$202K | ﹤0.01% | 1027 |
|
|
2022
Q3 | – | Sell |
-3,462
| Closed | -$206K | – | 1157 |
|
|
2022
Q2 | $206K | Sell |
3,462
-696
| -17% | -$42.8K | ﹤0.01% | 1075 |
|
|
2022
Q1 | $302K | Buy |
4,158
+547
| +15% | +$38.1K | ﹤0.01% | 1030 |
|
|
2021
Q4 | $304K | Sell |
3,611
-92
| -2% | -$7.49K | ﹤0.01% | 1072 |
|
|
2021
Q3 | $334K | Buy |
+3,703
| New | +$335K | ﹤0.01% | 1031 |
|
|
2021
Q2 | – | Sell |
-1,833
| Closed | -$209K | – | 1223 |
|
|
2021
Q1 | $209K | Sell |
1,833
-665
| -27% | -$90.5K | ﹤0.01% | 1105 |
|
|
2020
Q4 | $346K | Sell |
2,498
-728
| -23% | -$86.4K | 0.01% | 968 |
|
|
2020
Q3 | $265K | Buy |
+3,226
| New | +$267K | 0.01% | 970 |
|
|
2020
Q2 | – | Sell |
-2,248
| Closed | -$100K | – | 1349 |
|
|
2020
Q1 | $100K | Buy |
2,248
+1,471
| +189% | +$76.4K | ﹤0.01% | 1105 |
|
|
2019
Q4 | $33K | Buy |
777
+58
| +8% | +$2.39K | ﹤0.01% | 1397 |
|
|
2019
Q3 | $31K | Buy |
719
+18
| +3% | +$978 | ﹤0.01% | 1407 |
|
|
2019
Q2 | $45K | Sell |
701
-359
| -34% | -$22.9K | ﹤0.01% | 1393 |
|
|
2019
Q1 | $74K | Sell |
1,060
-197
| -16% | -$11.3K | ﹤0.01% | 1292 |
|
|
2018
Q4 | $55K | Buy |
+1,257
| New | +$68.7K | ﹤0.01% | 1327 |
|
|
2017
Q4 | – | Sell |
-382
| Closed | -$20K | – | 1395 |
|
|
2017
Q3 | $20K | Buy |
382
+38
| +11% | +$2.25K | ﹤0.01% | 1489 |
|
|
2017
Q2 | $21K | Buy |
344
+103
| +43% | +$6.21K | ﹤0.01% | 1464 |
|
|
2017
Q1 | $16K | Buy |
+241
| New | +$18.4K | ﹤0.01% | 1496 |
|
Other funds holding RARE
RI
FCM
Oppenheimer Asset Management's RARE Position: Q2 2026 in Review
Oppenheimer Asset Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 6,604 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1060 among its holdings. This is a return to the name: Oppenheimer Asset Management previously reported a position in RARE as recently as Q3 2025.
Oppenheimer Asset Management first reported a position in RARE in Q1 2017 and has held it in 29 quarters since. The position peaked at $361K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Oppenheimer Asset Management held 6,604 shares of Ultragenyx Pharmaceutical worth $221K as of Q2 2026.
- Ultragenyx Pharmaceutical was a new Oppenheimer Asset Management position in Q2 2026.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #1060 holding.
- Oppenheimer Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 29 quarters since.
- Oppenheimer Asset Management's Ultragenyx Pharmaceutical position peaked at $361K in Q3 2024.
- 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.